ThinkCyte
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $15.3m | Series A | |
$26.0m | Series B | ||
* | $24.0m Valuation: $130m | Series C | |
* | $7.4m | Debt | |
* | $7.4m Valuation: $130m | Series C | |
Total Funding | €70.2m |
Related Content
Recent News about ThinkCyte
EditThinkCyte is a biotechnology company that specializes in advanced cell sorting and profiling technologies. The company serves scientists and biomedical professionals by providing a transformational single-cell technology that accelerates biological discoveries and enables the development of novel treatments and diagnostics. Operating in the life sciences market, ThinkCyte integrates traditional fluorescence flow cytometry with high-dimensional morphological profiling and artificial intelligence to achieve label-free cell sorting and unbiased single-cell profiling at record high throughput rates. The business model revolves around selling its proprietary hardware and software solutions to research institutions, pharmaceutical companies, and biotech firms. Revenue is generated through the sale of these technologies, as well as through partnerships and collaborations aimed at accelerating research and development of novel therapeutics and AI-based approaches in life science.
Keywords: cell sorting, AI, morphological profiling, biotechnology, single-cell technology, diagnostics, therapeutics, high throughput, life sciences, research partnerships.